Elan

Elan EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Elan (6099.T) as of Nov 1, 2026 is 10.55. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 12.45 — a change of -15.29% (lower).

EV/EBIT

10.55

YoY

-15.29%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Elan is 2025 10.55 . EV/EBIT (Enterprise Value to EBIT) of Elan was 2024 12.45 . It decreases by -15.29% lower compared to the previous year.

The Elan EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
29.86 JPY
Jan 1, 2020
21.54 JPY
Jan 1, 2021
15.92 JPY
Jan 1, 2022
13.14 JPY
Jan 1, 2023
12.16 JPY
Jan 1, 2024
12.45 JPY
Jan 1, 2025
10.55 JPY
Jan 1, 2026 (e)
9.36 JPY
The Elan EV/EBIT history
YEAREV/EBITYoY
est9.36-11.28%
10.55-15.29%
12.45+2.45%
12.16-7.48%
13.14-17.47%
15.92-26.10%
21.54-27.84%
29.86-14.32%
34.85-28.61%
48.81-19.37%
60.54-20.05%
75.72-26.31%
102.75—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Elan Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Elan's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Elan's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Elan's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Elan grows earnings faster than its peers.

Elan Stock analysis

What does Elan do? Elan Corp is an Irish pharmaceutical company specializing in the research, development, and marketing of medications for neurological and autoimmune diseases. The company was founded in 1969 under the name Athlone Laboratories and has since undergone significant changes in both its business fields and its name. In 1996, the company was renamed Elan Corporation, a name it still holds today. At that time, the company primarily focused on researching and developing medications for Alzheimer's and Parkinson's diseases. However, in the following years, the company shifted its focus more towards treating autoimmune diseases such as multiple sclerosis and Crohn's disease. Elan Corp's business model is based on the development of medications through research and development as well as the acquisition of established therapeutics. One key component of the product portfolio is the medication Tysabri, which was developed in collaboration with Biogen Idec. It is used to treat multiple sclerosis patients and is one of Elan's top-selling medications, contributing significantly to the company's success. Elan Corp consists of three main business areas: 1. Biopharmaceuticals This division is responsible for the research and development of medications for neurological diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. Some of the key products in this area, in addition to Tysabri, include Axona, a nutritional supplement to enhance cognitive function in Alzheimer's patients, and Zanaflex, which is used to treat muscle spasms in the majority of multiple sclerosis patients. 2. Neurology In this division, Elan focuses on the marketing and distribution of nerve and pain medications, as well as products for treating infections. Some of the key products in this area are Skelaxin, a muscle relaxant for pain and muscle spasms, and Biaxin, an antibiotic for treating infections. 3. Medical Technology Elan Corp's medical technology division specializes in the development and marketing of infusion pumps. The company primarily offers its products and services in the United States and Europe and holds a strong position in this market. Elan Corp is a company with a strong focus on research and development. Its key products are medications for treating neurological and autoimmune diseases, with Tysabri being the most well-known and successful. The company has undergone significant changes over the years and now focuses on developing medications for autoimmune diseases in the neurology field. With a strong emphasis on research and development, as well as the acquisition of established therapeutics, Elan Corp is an important player in the pharmaceutical industry and is expected to continue growing and succeeding in the future. Elan is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Elan stock

EV/EBIT (Enterprise Value to EBIT) of Elan is 10.55 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Elan changed from 12.45 to 10.55, representing a -15.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Elan since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Elan with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Elan

All Key Metrics — Elan